Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie av THERMOCOOL SMARTTOUCH Surround Flow (SF) kateter med TRUPULSE-generator for behandling av medikamentrefraktær symptomatisk PAFOUS (PulseSmart)

26. oktober 2026 oppdatert av: Biosense Webster, Inc.

Sikkerhet og effektivitetsevaluering av THERMOCOOL SMARTTOUCH™ SF-kateter med TRUPULSE™-generator for behandling av medikamentrefraktær symptomatisk paroksysmal atrieflimmer (PAF)

The purpose of this study is to demonstrate safety and effectiveness of the Biosense Webster (BWI) ablation system (THERMOCOOL SMARTTOUCH surround flow [STSF] catheter and TRUPULSE generator) when used for isolation of the atrial pulmonary veins (PVs) in treatment of participants with paroxysmal atrial fibrillation (PAF), an irregular heart rate that causing abnormal blood flow.

Studieoversikt

Status

Fullført

Forhold

Studietype

Intervensjonell

Registrering (Faktiske)

136

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Camperdown, Australia, 2050
        • Royal Prince Alfred Hospital
      • Garran, Australia, 2605
        • Canberra Heart Rhythm
      • Westmead, Australia, 2145
        • Westmead Hospital
    • Ontario
      • Newmarket, Ontario, Canada, L3Y 2P9
        • Southlake Regional Health Centre
      • Ottawa, Ontario, Canada, K1Y 4W7
        • University of Ottawa Heart Institute
    • Quebec
      • Montreal, Quebec, Canada, H3G 1A4
        • McGill University Health Centre
      • Montreal, Quebec, Canada, H1T 1C8
        • Montreal Heart Institute

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 80 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria::

  • Diagnosed with Symptomatic PAF (Physician's note indicating recurrent self-terminating AF). At least one (1) electrocardiographically documented AF episode within twelve (12) months prior to enrollment. Electrocardiographic documentation may include, but is not limited to, electrocardiogram (ECG), Holter monitor, or other electrocardiographical devices accepted by investigators
  • Failed at least one (1) Class I or Class III Antiarrhythmic Drug (AAD) as evidenced by recurrent symptomatic AF or has intolerable side effects or is contraindicated to the Class I or Class III AAD
  • Able and willing to comply with all pre-procedure, post-procedure, and follow-up testing and visit requirements
  • Willing and capable of providing consent

Exclusion Criteria:

  • AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause (e.g., untreated documented obstructive sleep apnea and acute alcohol toxicity)
  • Previous LA ablation or surgery
  • Patients known to require ablation outside the PV region (atrioventricular reentrant tachycardia, atrioventricular nodal reentry tachycardia, atrial tachycardia, atrial flutter of unknown origin, ventricular tachycardia and Wolff-Parkinson-White)
  • Previously diagnosed with persistent AF (> 7 days in duration)
  • Severe dilatation of the LA (documented LAD >50mm antero-posterior diameter on imaging within 6 months prior to enrollment
  • Documented left atrium (LA) thrombus within 48 hours prior to the index procedure by Transesophageal Echocardiography (TEE), or by Intracardiac Echocardiography (ICE) prior to transeptal puncture during procedure
  • Documented severely compromised LVEF (LVEF <40%) by imaging within 6 months prior to enrollment
  • Uncontrolled heart failure or New York Heart Association (NYHA) Class III or IV
  • History of blood clotting, bleeding abnormalities or contraindication to anticoagulation (heparin, warfarin, or dabigatran)
  • History of a documented thromboembolic event (including TIA) within the past 12 months, or history of a documented left atrial appendage (LAA) thrombus
  • History of a documented symptomatic lacunar infarction within the past 12 months
  • Previous PCI/MI within the past 2 months
  • Coronary Artery Bypass Grafting (CABG) surgery within past 6 months
  • Valvular surgery, cardiac surgery (e.g., ventriculotomy, atriotomy) or valvular cardiac (surgical or percutaneous) procedure
  • Unstable angina pectoris within the past 6 months
  • Anticipated cardiac transplantation, cardiac surgery or other major surgery within the next 12 months
  • Significant pulmonary disease (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms
  • Known significant PV anomaly that in the opinion of the investigator would preclude enrollment in this study
  • Has known pulmonary vein stenosis
  • Pre-existing hemi diaphragmatic paralysis
  • Acute illness, active systemic infection or sepsis
  • Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation
  • Severe mitral regurgitation (Regurgitant volume 60 mL/beat, Regurgitant fraction 50%, and/or Effective regurgitant orifice area 0.40cm^2)
  • Presence of implanted pacemaker, Implantable Cardioverter-Defibrillator (ICD), recently implanted (within 6 months) LAAO device or other implanted metal cardiac device within the cardiac space that may interfere with the energy field created during the ablation procedure.
  • Presence of a condition that precludes vascular access (such as IVC filter)
  • Significant congenital anomaly or a medical problem that in the opinion of the investigator would preclude enrollment in this study
  • Categorized as vulnerable population and requires special treatment with respect to safeguards of well-being
  • Current enrollment in an investigational study evaluating another device or drug
  • Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of childbearing age and plan on becoming pregnant during the course of the clinical investigation
  • Life expectancy less than 12 months
  • History of massive hemorrhage within the past 6 months
  • Presenting contra-indications for the devices

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Pulsed Field (PF)/Radiofrequency (RF) Ablation System

Participants with drug refractory symptomatic PAF who are candidates for atrial fibrillation ablation uses PF and RF energy to produce targeted intracardiac lesions for the treatment of atrial fibrillation.

THERMOCOOL STSF catheter will be used in conjunction with TRUPULSE Generator to give PF ablation or RF ablation.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Participants With Primary Adverse Events (PAEs)
Tidsramme: Up to 12 Months post ablation procedure on Day 0

An adverse event (AE) was any untoward medical occurrence, unintended disease or injury or any untoward clinical signs, including abnormal laboratory finding, in participants or users in context of clinical investigation, whether or not related to device/procedure. PAEs included the following adverse events: Device or procedure related death within 30 days of ablation procedure, esophageal perforating complications (atrio-esophageal fistula [up to 90 days post ablation procedure], esophago-pericardial fistula), myocardial infarction, cardiac tamponade/perforation up to 30 days post ablation, thromboembolism, stroke/cerebrovascular accident (CVA), transient ischemic attack (TIA), phrenic nerve paralysis, pulmonary vein stenosis (occurring anytime during 12 month follow-up period considered a PAE), major vascular access complication/bleeding, pericarditis, heart block, pulmonary edema (respiratory insufficiency), and vagal nerve injury/gastroparesis.

Up to 12 Months post ablation procedure on Day 0
Percentage of Participants With Freedom From Documented (Symptomatic and Asymptomatic) Atrial Arrhythmia (Atrial Fibrillation [AF], Atrial Tachycardia [AT] or Atrial Flutter [AFL]) Episodes Based on Electrocardiographic Data and From All Failure Modes
Tidsramme: From Day 91 up to Day 365 post ablation procedure on Day 0

Percentage of participants with freedom from documented (symptomatic and asymptomatic) atrial arrhythmia (AF, AT or AFL) episodes based on electrocardiographic data and from all failure modes were reported. Atrial tachyarrhythmia (AF/AT/AFL of unknown origin) episodes were based on electrocardiographic data [12-lead electrocardiogram(ECG) or greater than or equal to(>=) 30 seconds on ECG or sponsor provided transtelephonic monitor (TTM) or Holter device] during effectiveness evaluation period (Day 91 to Day 365) and any of following failure modes: acute procedural, repeat ablation, non-study device, anti-arrhythmic drug (AAD), continuous AF/AT/AFL of unknown origin, and any direct current cardioversion procedure during evaluation period for documented atrial tachyarrhythmia (AF/AT/AFL of unknown origin). AFL of unknown origin was defined as all AFL except those cavotricuspid isthmus dependent AFL as confirmed by 12-Lead ECG and entrainment maneuvers in an electrophysiology (EP) study.

From Day 91 up to Day 365 post ablation procedure on Day 0

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change From Baseline in Atrial Fibrillation Effect on Quality of Life (AFEQT) Total Score at Month 12
Tidsramme: Baseline, Month 12

Change from baseline in AFEQT total score at Month 12 was reported. AFEQT questionnaire was used to assess the quality-of-life post ablation procedure. The AFEQT questionnaire included 20 questions on a 7-point Likert scale. Questions 1-18 evaluated health-related quality of life (HRQoL), including AF-related symptoms (Questions 1-4), daily activities (Questions 5-12), and treatment concerns (Questions 13-18), while Questions 19-20 assessed participant satisfaction with treatment. The first 18 questions were used to calculate the overall AFEQT scores. Scores are transformed to a scale ranging from 0 to 100, where a score of 0 indicated complete disability and a score of 100 indicated no disability. Higher scores indicated improvement. The formula to calculate these scores is as follows:

100 minus([sum of severity for all questions answered minus number of questions answered]*100 divided by total number questions answered*6).

Baseline, Month 12

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Biosense Webster, Inc. Clinical Trial, Biosense Webster, Inc.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

28. februar 2024

Primær fullføring (Faktiske)

28. oktober 2025

Studiet fullført (Faktiske)

28. oktober 2025

Datoer for studieregistrering

Først innsendt

15. februar 2024

Først innsendt som oppfylte QC-kriteriene

15. februar 2024

Først lagt ut (Faktiske)

22. februar 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

26. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere